HCM
ABCL icon

Hollencrest Capital Management’s AbCellera Biologics ABCL Stock Holding History

Hollencrest Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,000
Closed -$25.1K – 1171
2025
Q3 		$25.1K Buy
+5,000
New +$22K ﹤0.01% 672

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hollencrest Capital Management's ABCL Position: Q4 2025 in Review

Hollencrest Capital Management sold out of AbCellera Biologics (ABCL) in Q4 2025, closing a stake of 5,000 shares — an estimated $25.1K sold.

Hollencrest Capital Management first reported a position in ABCL in Q3 2025 and held it in 1 quarter. The position peaked at $25.1K in Q3 2025. 144 funds tracked by Wall St. Rank hold ABCL as of Q4 2025.

  • Hollencrest Capital Management reported no remaining AbCellera Biologics position as of Q4 2025 after selling out during the quarter.
  • Hollencrest Capital Management sold 5,000 AbCellera Biologics shares in Q4 2025, an estimated $25.1K.
  • Hollencrest Capital Management first reported a position in AbCellera Biologics in Q3 2025 and held it in 1 quarter.
  • Hollencrest Capital Management's AbCellera Biologics position peaked at $25.1K in Q3 2025.
  • 144 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2025.

Based on Hollencrest Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.